Research Article| Volume 180, ISSUE 1, P161-169, May 2005

Association between insulin resistance and apolipoprotein B in normoglycemic Koreans

  • Ki Chul Sung
    Corresponding author. Tel.: +82 2 2001 2050/11 9050 4098; fax: +82 2 2001 2400/2049.
    Division of Cardiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Pyung Dong, Jongro-Ku, Seoul 110 746, Republic of Korea
    Search for articles by this author
  • Sang Tai Hwang
    Division of Cardiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Pyung Dong, Jongro-Ku, Seoul 110 746, Republic of Korea
    Search for articles by this author



      Insulin resistance (IR) is associated with a significant increase in the risk of coronary artery disease (CAD). The serum apolipoprotein B and Apo A1/Apo B ratio are important markers of CAD. The aim of this study was to assess the association of the serum Apo B and Apo A1/Apo B ratio, with insulin resistance in apparently healthy normoglycemic Koreans.


      From the individuals that participated in medical screening at the health promotion center of Kangbuk Samsung Hospital, between January and December 2002, a total of 7427 participants (4356 men, 3071 women) were enrolled in this study. All participants had no personal histories of diabetes, with normal fasting glucose levels. The clinical characteristics and biochemical parameters of the subjects were assessed.


      The Apo B, total cholesterol/high-density lipoprotein-cholesterol (HDL-C) and low-density lipoprotein-cholesterol (LDL-C)/high-density lipoprotein-cholesterol showed positive correlations with metabolic syndrome and insulin resistance (p < 0.001). The Apo A1, Apo A1/Apo B, LDL/Apo B and HDL/Apo A1 showed negative correlations with metabolic syndrome and insulin resistance (p < 0.001).


      These data suggest that insulin resistance may be associated with the serum Apo B and Apo A1/Apo B ratio in non-diabetic, normoglycemic subjects. Thus, further study may be needed to determine whether medical intervention is inevitable or not in these type of subjects.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mykkanen L.
        • Zaccaro D.J.
        • Wagenknecht L.E.
        • et al.
        Microalbuminuria is associated with insulin resistance in non-diabetic subjects: the Insulin Resistance Atherosclerosis Study.
        Diabetes. 1998; 47: 793-800
        • DeFonzo R.A.
        • Ferrannini E.
        Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.
        Diab Care. 1991; 14: 173-194
        • Kaplan N.M.
        The deadly guartet: upper-body obesity, glucose intolerance, hyper-triglyceridemia, and hypertension.
        Arch Intern Med. 1989; 149: 1514-1520
        • Angela D.L.
        • Elizabeth J.
        • Mayer D.
        • et al.
        Development of the multiple metabolic syndrome in the ARIC Cohort: Joint contribution of insulin, BMI, and WHR.
        AEP. 1997; 7: 407-416
        • Reaven G.M.
        Insulin resistance and compensatory hyperinsulinemia: role in hypertension, dyslipidemia and coronary artery disease.
        Am Heart J. 1991; 121: 1283
      1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486–97.

        • Scott M.
        • Grundy
        Approach to lipoprotein management in 2001 National Cholesterol Guidelines.
        Am J Cardiol. 2002; 17: 11i-21i
        • Lamarche B.
        • Tchernof A.
        • Moorjani S.
        • et al.
        Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.
        Circulation. 1997; 95: 69-75
        • Talmud P.J.
        • Hawe E.
        • Miller G.J.
        • Humphries S.E.
        Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1918-1923
        • Rahmani M.
        • Raiszadeh F.
        • Allahverdin S.
        • et al.
        Coronary artery disease is associated with the ratio of apolipoprotein A-I/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects.
        Atherosclerosis. 2002; 162: 381-389
        • Wagner A.M.
        • Perez A.
        • Zapico E.
        • Ordonez-Llanos J.
        Non-HDL-cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients.
        Diab Care. 2003; 26: 2048-2051
        • Walldius G.
        • Jungner I.
        • Holme I.
        • et al.
        High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study.
        Lancet. 2001; 358: 2026-2033
        • Sniderman A.D.
        • Furberg C.D.
        • Keech A.
        • et al.
        Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment.
        Lancet. 2003; 361: 777-780
        • Zavaroni I.
        • Bonora E.
        • Pagliara M.
        • et al.
        Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance.
        N Engl J Med. 1989; 320: 702-706
        • Hsieh A.T.
        • Chu N.F.
        • Shen M.H.
        • et al.
        Insulin, proinsulin and insulin resistance status in relation to lipid profiles among school children in Taiwan—The Taipei Children Heart Study.
        Clin Biochem. 2003; 36: 367-372
        • Despres J.P.
        • Lamarche B.
        • Mauriege P.
        • et al.
        Hyperinsulinemia as an independent risk factor for ischemic heart disease.
        N Engl J Med. 1996; 334: 952-957
        • Elovson J.
        • Chatterton J.E.
        • Bell G.T.
        • et al.
        Plasma very low-density lipoproteins contain a single molecule of apolipoprotein B.
        J Lipid Res. 1988; 29: 1461-1473
        • Sniderman A.D.
        • Scantlebury T.
        • Cianflone K.
        Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.
        Ann Intern Med. 2001; 135: 447-459
        • Lamarche B.
        • Moorjani S.
        • Lupien P.J.
        • et al.
        Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec Cardiovascular Study.
        Circulation. 1996; 94: 273-278
        • Lemieux I.
        • Lamarche B.
        • Couillord C.
        • et al.
        Total cholesterol/HDL-cholesterol ratio versus LDL-cholesterol/HDL-cholesterol ratio as indices of ischemic heart disease risk in men: The Quebec Cardiovascular Study.
        Arch Intern Med. 2001; 161: 2685-2692
        • Taghibiglou C.
        • Carpentier A.
        • Van Iderstine S.C.
        • et al.
        Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model.
        J Biol Chem. 2000; 275: 8416-8425
        • Taghibiglou C.
        • Rashid-Kolvear F.
        • Van Iderstine S.C.
        • et al.
        Hepatic very low-density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance.
        J Biol Chem. 2002; 277: 793-803